Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reacting to the Crisis: Biotech Venture Capital's Plan B

This article was originally published in Start Up

Executive Summary

There are significant dilemmas facing life sciences venture capitalists buffeted by the simultaneous but distinct insults of global financial calamity and trickier-than-ever biotech partnering, regulatory, and reimbursement environments. Venture's best bet at a return is an uptick in decidedly un-venture PIPE deals that take advantage of public biotechs' miserable valuations, but those deals aren't exactly growing on trees. Despite the surfeit of bad news, there may be a bright side.

Related Content

Biotech Angels Are Going Where VCs Fear To Tread
In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math
Use Of Protein Biomarkers Punctuates Clovis' Fast-Paced Clinical Trials Strategy
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2009
Valuation Watch: Bargain Prices Not Enough to Flood PIPEs
With Capital Scarce, Charities Emerge as a Stronger Force on Start-Up Scene
The A-List: 2008's Trend Shaping Series A Financings
Biopharma in 2008: What a Difference an Economic Crisis Makes
Private Biotech M&A Review: Has the Market Lost Steam?
Venture Philanthropy: The New Venture Capital?


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts